RESUMEN
In 2023, the improvement of our therapeutic management has largely taken shape. The aim of our article is to highlight the major advances that will change our practices. These are not only in the field of treatment, but also in the improvement of supportive care. Here, we present these new developments organ by organ, cancer by cancer. You can read everything or concentrate on the cancers that are your areas of expertise. But this exhaustiveness should be representative of our current state of progress.
Asunto(s)
Neoplasias , Humanos , Neoplasias/terapia , Oncología MédicaRESUMEN
The Cancer Bulletin continues its tradition. At the beginning of 2023, the members of the editorial committee would like to share with you their analyses of the highlights of 2022. The objective remains to highlight what will change our practices and lead to different diagnostic or therapeutic options. Our synthesis will therefore focus on published data. They have been analyzed and placed in the more general context of the management of each type of cancer to deduce the practical consequences for our patients. This synthesis exercise will concern almost all tumor pathologies, most often on the therapeutic level, and will, however, exclude the evolution of techniques, whether they are diagnostic or used for the follow-up of our patients. The final objective is to allow you to have a thoughtful, didactic and practical reading. Our goal is to provide our readers with the rational bases that can lead to a different approach for treatments in 2023.
Asunto(s)
Oncología Médica , Neoplasias , Humanos , Neoplasias/diagnóstico , Neoplasias/terapiaRESUMEN
Once again this year, the Editorial Board presents here a summary of the most important advances in treatment and patient care in oncology over the past year. Some of the most important results in breast and gynecological cancers (endometrium and cervix), lung, brain, urologic and digestive cancers. Are also presented progresses in hematological malignancies, pediatric oncology, and of course supportive care essential for our patients.
Asunto(s)
Oncología Médica/tendencias , Neoplasias/terapia , Antineoplásicos/uso terapéutico , Neoplasias Encefálicas/terapia , Neoplasias de la Mama/terapia , Ensayos Clínicos como Asunto , Neoplasias Endometriales/terapia , Femenino , Neoplasias Gastrointestinales/terapia , Neoplasias Hematológicas/terapia , Humanos , Inmunoterapia , Neoplasias Pulmonares/terapia , Masculino , Neoplasias de la Próstata/terapia , Rabdomiosarcoma/terapia , Neoplasias Urológicas/terapia , Neoplasias del Cuello Uterino/terapiaRESUMEN
The editorial committee of the Bulletin du Cancer is proud to comply with his annual analysis of some of the worldwide updates in oncology that emerge in 2020. We know that all new breakthroughs will not be addressed and apologise for not being comprehensive, but we hope that the topics deciphered herein will bring the reader interesting information in his daily practice in gyneco-oncology, uro-oncology, neuro-oncology, digestive oncology, pneumo-oncology, hemato-oncology, pediatric oncology, or in palliative care.
Asunto(s)
Oncología Médica , Neoplasias/terapia , Antineoplásicos/uso terapéutico , Neoplasias Encefálicas/terapia , Neoplasias del Sistema Digestivo/terapia , Femenino , Neoplasias de los Genitales Femeninos/terapia , Glioblastoma/terapia , Neoplasias Hematológicas/terapia , Humanos , Neoplasias Pulmonares/terapia , Masculino , Neoplasias Primarias Desconocidas/terapia , Neoplasias de la Próstata Resistentes a la Castración/genética , Neoplasias de la Próstata Resistentes a la Castración/terapia , Neoplasias Urológicas/terapiaRESUMEN
The editorial board of Bulletin du Cancer presents some hot topics published or presented in major oncology meetings in 2018. This selection is related to pediatric oncology and to solid and hemato-malignancies in adults, with immunotherapy approaches (checkpoints or CAR-T) as one of the major breakthroughs. Putative impacts on daily practices are discussed, in order to detail what will really change our practice.
Asunto(s)
Oncología Médica/tendencias , Neoplasias/terapia , Adulto , Niño , Ensayos Clínicos como Asunto , Neoplasias Hematológicas/terapia , Humanos , Inmunoterapia/tendenciasRESUMEN
Actuality was dense in 2017 for oncology and hematology. The editorial board of the Bulletin du Cancer proposes a selection of key data distinguishing four trends: precision medicine, immunotherapy, focus on early stages and global management of metastatic disease. A summary of results which have been published or presented in congresses is proposed and the impact on daily practices is discussed.
Asunto(s)
Inmunoterapia/tendencias , Oncología Médica/tendencias , Metástasis de la Neoplasia/terapia , Neoplasias/terapia , Medicina de Precisión/tendencias , Radioterapia de Iones Pesados/tendencias , Humanos , Neoplasias/patología , Inhibidores de Poli(ADP-Ribosa) Polimerasas , Terapia de Protones/tendenciasAsunto(s)
Neoplasias , Publicaciones Periódicas como Asunto , Francia , Humanos , Normas Sociales , Factores de TiempoAsunto(s)
Oncología Médica , Publicaciones Periódicas como Asunto , Sociedades Médicas , Congresos como Asunto/organización & administración , Difusión de Innovaciones , Políticas Editoriales , Francia , Humanos , Oncología Médica/organización & administración , Oncología Médica/tendencias , Neoplasias/tratamiento farmacológico , Terapias en InvestigaciónRESUMEN
The vascular endothelial growth factors (VEGF) plays major roles during tumor development. VEGF expression is regulated by the transcription factor HIF (hypoxia inducible factor) which is very sensitive to oxygene variations. We will show here that HIF1alpha is today a good prognostic and diagnostic marker for an increasing number of cancers from various origins. Furthermore, the reduction of the expression or the activity of HIF1alpha impairs tumour angiogenesis and subsequently growth. Altogether, these results suggest that HIF1alpha could be an interesting target in cancer therapy.
Asunto(s)
Biomarcadores de Tumor/fisiología , Hipoxia de la Célula/fisiología , Proteínas de Unión al ADN/fisiología , Factores de Crecimiento Endotelial/fisiología , Linfocinas/fisiología , Neoplasias/metabolismo , Neovascularización Fisiológica/fisiología , Proteínas Nucleares/fisiología , Factores de Transcripción , Animales , Biomarcadores de Tumor/antagonistas & inhibidores , Proteínas de Unión al ADN/antagonistas & inhibidores , Factores de Crecimiento Endotelial/antagonistas & inhibidores , Factores de Crecimiento Endotelial/genética , Regulación de la Expresión Génica , Humanos , Factor 1 Inducible por Hipoxia , Subunidad alfa del Factor 1 Inducible por Hipoxia , Linfocinas/antagonistas & inhibidores , Linfocinas/genética , Neoplasias/irrigación sanguínea , Neoplasias/terapia , Proteínas Nucleares/antagonistas & inhibidores , ARN sin Sentido/uso terapéutico , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
The proteasome degradation system is one of the most efficient proteolytic process in living cells. We will focus here on a new compound, called PS341, which is the first proteasome inhibitor entering clinical phases. First results about its use in multiple myeloma or leukemic cells will be discussed.
Asunto(s)
Antineoplásicos/uso terapéutico , Ácidos Borónicos/uso terapéutico , Neoplasias/tratamiento farmacológico , Inhibidores de Proteasas/uso terapéutico , Pirazinas/uso terapéutico , Animales , Bortezomib , Ensayos Clínicos Fase I como Asunto , HumanosRESUMEN
The topic of this review is first to analyze in normal conditions the signal transduction pathways induced by members of the HER-ErbB receptor family and their ligands, and second, to decipher some deregulations occurring in various cancer types. As a result, new therapeutic opportunities will be mentioned.